chevron_leftBack
As of 6 June 2026, Solasia Pharma K.K. has a market cap of $58.0M USD, ranking #29508 globally and #2719 in Japan.
It ranks #2674 in the Healthcare sector, and #947 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$58.0MUSD
9.28B JPY
Enterprise Value
$49.93MUSD
7.99B JPY
Revenue (TTM)
$2.68MUSD
429.0M JPY
EBITDA (TTM)
-$5.14MUSD
-822.0M JPY
Net Income (TTM)
-$5.47MUSD
-876.0M JPY
EBITDA Margin
-192%
Profit Margin
-204%
PS Ratio
21.6
PB Ratio
5.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yoshihiro Arai
open_in_new
Employees
22
Founded
2006
Website
solasia.co.jp
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.9% | -17% | 3% | 13% | -2.9% | 6.3% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4597
ソレイジア・ファーマ株式会社
ISIN: JP3436500007
Shares Out.:
Shares Outstanding:
273.005M1
Shares Float:
244.589M2
|
33 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Solasia Pharma K.K.
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TSE: 4519
|
$81.66B
141K%
13.07T JPY
|
28.9
|
|
TSE: 4502
|
$52.21B
90K%
8.36T JPY
|
75.1
|
|
TSE: 4578
|
$36.84B
63K%
5.9T JPY
|
15.7
|
|
TSE: 4568
|
$30.37B
52K%
4.86T JPY
|
16.2
|
|
TSE: 4503
|
$25.82B
44K%
4.13T JPY
|
14.2
|
|
TSE: 4507
|
$16.91B
29K%
2.71T JPY
|
13.9
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
943K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
622K%
|
97.4
|
|
SIX: RO
|
$324.68B
560K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
499K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
478K%
218.9B CHF
|
20.5
|
chevron_leftBack